The Next Cox-2 Battle: Merck, Novartis Drugs Face Vocal Resistance
This article was originally published in RPM Report
Executive Summary
Novartis AG and Merck & Co. Inc. beware: Steven Nissen doesn't want your investigational cox-2 inhibitors to win approval from the Food & Drug Administration.
You may also be interested in...
Inside the Mind of a Serial Drug Killer
The Cleveland Clinic's Steve Nissen has taken it upon himself to lead a drug safety crusade on behalf of patients that has ruined some high-profile drugs, elevated his status in the scientific world and captivated the drug industry. Why is he doing it-and will he continue?
Inside the Mind of a Serial Drug Killer
The Cleveland Clinic's Steve Nissen has taken it upon himself to lead a drug safety crusade on behalf of patients that has ruined some high-profile drugs, elevated his status in the scientific world and captivated the drug industry. Why is he doing it-and will he continue?
The Death of Arcoxia: Drug Regulation in a "Whistleblower" Climate
There may not be a worse time to push a new drug through FDA-especially a "me-too" product with a questionable benefit-risk profile. Until Congress releases its grasp on the approval process, FDA isn't taking any chances. Unfortunately for industry, a few drugs are getting caught in the crossfire. Merck seemed unprepared for the new climate with Arcoxia; will other sponsors learn the lesson?